Currently, the treatment of advanced NSCLC relies on molecular testing for predictive biomarkers, including oncogenic drivers, to determine eligibility for targeted therapies such as those for EGFR, ALK, ROS1, BRAF, HER2, MET, RET, or KRASG12C. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.